Duodenal Ulcer Treatment Market To Reach $5.54 Billion By 2030

Duodenal Ulcer Treatment Market Growth & Trends

The global duodenal ulcer treatment market size is anticipated to reach USD 5.54 billion in 2030 and is anticipated to grow at a CAGR of 3.2% from 2025 to 2030. The market encompasses a range of elements focused on the management and treatment of duodenal ulcers, which are sores that occur in the lining of the duodenum.

Pharmacological treatments are crucial to the duodenal ulcer treatment market. These medications include proton pump inhibitors (PPIs), histamine receptor antagonists (H2RAs), and antibiotics targeting Helicobacter pylori infections, mucosal protectants, and antacids. These medications reduce gastric acid production, eradicate bacterial pathogens, enhance mucosal defense, or neutralize stomach acid. This therapeutic approach alleviates bloating, abdominal pain, and discomfort while accelerating ulcer healing.

The market is experiencing significant growth due to the incorporation of digital health solutions such as mobile apps, telemedicine platforms, and remote monitoring tools. These technologies enable personalized treatment management, real-time symptom tracking, and enhanced patient engagement. Additionally, artificial intelligence (AI) algorithms are being employed to analyze large datasets, which improves treatment outcomes and facilitates early detection of ulcer issues.

 Request a free sample copy or view report summary: Duodenal Ulcer Treatment Market Report

Duodenal Ulcer Treatment Market Report Highlights

• The proton pump inhibitors segment dominated the market with a revenue share of 52.1% in 2024, driven by the increasing prevalence of gastrointestinal disorders, particularly among the aging population, who are more susceptible to conditions such as duodenal ulcers

• The oral segment dominated the market with the largest revenue share in 2024, driven by patient preference for non-invasive treatment options that offer ease of administration and convenience

• The retail pharmacies segment dominated the market with the largest revenue share in 2024, fueled by the accessibility and convenience that retail pharmacies provide for patients seeking over-the-counter medications for duodenal ulcers

• North America duodenal ulcer treatment market held the highest revenue share of 39.5% in 2024, fueled by the advanced healthcare infrastructure and high levels of healthcare spending among consumers

• The hospital pharmacies segment is projected to grow at the significant CAGR over the forecast period,

Duodenal Ulcer Treatment Market Segmentation

Grand View Research has segmented the global duodenal ulcer treatment market based on treatment, route of administration, distribution channel, and region:

Duodenal Ulcer Treatment Treatment Outlook (Revenue, USD Billion, 2018 - 2030)

• Proton Pump Inhibitors

• H2 Antagonists

• Antibiotics

• Other

Duodenal Ulcer Treatment Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

• Oral

• Parenteral

Duodenal Ulcer Treatment Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Other

Duodenal Ulcer Treatment Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.          

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Duodenal Ulcer Treatment Market

• GSK plc.

• Pfizer Inc.

• Novartis AG

• Merck KGaA

• NIHON GENERIC Co., Ltd.

• Abbott

• AstraZeneca

• Bristol-Myers Squibb Company

• Takeda Pharmaceutical Company Limited.

• Eisai Co., Ltd.